<DOC>
	<DOCNO>NCT02143687</DOCNO>
	<brief_summary>The purpose study investigate effect travel moderate altitude nocturnal oxygen therapy stay moderate altitude exercise performance patient pulmonary hypertension interstitial lung disease .</brief_summary>
	<brief_title>Patients With Pulmonary Hypertension Interstitial Lung Disease Altitude - Effect Oxygen Exercise Performance</brief_title>
	<detailed_description>Patients pulmonary hypertension interstitial lung disease live 800 invited participate randomize , cross-over field trial evaluate hypothesis : ) , exercise capacity 2 day sojourn moderate altitude reduce comparison low altitude ; b ) , exercise capacity 2 day sojourn moderate altitude improve nocturnal oxygen therapy compare room air ( sham oxygen ) administer night altitude . Outcomes assess low altitude ( Zurich , 490 , baseline ) , 2 study period 2 day spend moderate altitude ( St. Moritz Salastrains , 2048 ) , separate wash-out period least 2 week spend low altitude ( &lt; 800 ) . The order stay different altitude treatment randomize .</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Hypertension , Pulmonary</mesh_term>
	<mesh_term>Lung Diseases , Interstitial</mesh_term>
	<mesh_term>Sevoflurane</mesh_term>
	<criteria>Precapillary pulmonary hypertension , interstitial lung disease . New York Heart Association class 23 . Residence low altitude ( &lt; 800m ) . Unstable exacerbated condition Very severe pulmonary hypertension interstitial lung disease , New York Heart Association class 4 Requirement oxygen therapy low altitude residence Hypoventilation More mild unstable cardiovascular disease Use drug affect respiratory center drive Internal , neurologic psychiatric disease interfere protocol compliance include current heavy smoking ( &gt; 20 cigarette per day ) , inability perform 6 min walk test . Previous intolerance moderate altitude ( &lt; 2600m ) . Exposure altitudes &gt; 1500m &gt; 2 day within last 4 week study . Pregnant nursing patient</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Pulmonary hypertension</keyword>
	<keyword>Interstitial lung disease</keyword>
	<keyword>Pulmonary fibrosis</keyword>
</DOC>